# Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL

> **NCT06578546** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 30 (estimated)

## Conditions studied

- Ph-Positive Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Orebatinib

## Key facts

- **NCT ID:** NCT06578546
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06578546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06578546, "Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06578546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*